BR112018070084A2 - composições de célula viável, e métodos relacionados às mesmas - Google Patents

composições de célula viável, e métodos relacionados às mesmas

Info

Publication number
BR112018070084A2
BR112018070084A2 BR112018070084-3A BR112018070084A BR112018070084A2 BR 112018070084 A2 BR112018070084 A2 BR 112018070084A2 BR 112018070084 A BR112018070084 A BR 112018070084A BR 112018070084 A2 BR112018070084 A2 BR 112018070084A2
Authority
BR
Brazil
Prior art keywords
viable cell
viable
contain
composition
cell compositions
Prior art date
Application number
BR112018070084-3A
Other languages
English (en)
Inventor
Zacharias Shelly
J. Woods Erik
Original Assignee
Cook General Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook General Biotechnology Llc filed Critical Cook General Biotechnology Llc
Publication of BR112018070084A2 publication Critical patent/BR112018070084A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)

Abstract

divulgadas são composições de célula viável e métodos relacionados de preparação, manutenção e uso. a composição de célula viável pode conter níveis específicos de células, hidroxietil amido, e dimetilsulfóxido, e pode ser criopreservada. a forma criopreservada da composição pode ser descongelada e combinada com um meio de diluição de líquido aquoso para preparar uma composição de célula viável diluída que pode conter níveis reduzidos, específicos do dimetilsulfóxido e hidroxietil amido. o meio de diluição pode conter trealose. a composição de célula viável diluída, preparada pode ser administrada a um paciente.
BR112018070084-3A 2016-03-28 2017-03-28 composições de célula viável, e métodos relacionados às mesmas BR112018070084A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314316P 2016-03-28 2016-03-28
US62/314,316 2016-03-28
PCT/US2017/024411 WO2017172679A1 (en) 2016-03-28 2017-03-28 Viable cell compositions, and methods related to same

Publications (1)

Publication Number Publication Date
BR112018070084A2 true BR112018070084A2 (pt) 2019-02-19

Family

ID=58489765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070084-3A BR112018070084A2 (pt) 2016-03-28 2017-03-28 composições de célula viável, e métodos relacionados às mesmas

Country Status (8)

Country Link
US (2) US20170332623A1 (pt)
EP (1) EP3435762A1 (pt)
JP (1) JP2019510042A (pt)
CN (1) CN109195445A (pt)
AU (1) AU2017241626B2 (pt)
BR (1) BR112018070084A2 (pt)
CA (1) CA3022685A1 (pt)
WO (1) WO2017172679A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7072147B2 (ja) * 2018-09-13 2022-05-20 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
US20230158076A1 (en) * 2020-04-13 2023-05-25 National University Corporation Tokai National Higher Education And Research System Agent for increasing cd25-positive regulatory t cells in kidneys

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004975A (en) * 1975-12-30 1977-01-25 The United States Of America As Represented By The Secretary Of The Navy Method of isolating and cryopreserving human white cells from whole blood
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
DK0762897T3 (da) * 1994-06-02 2003-07-21 Elan Drug Delivery Ltd Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning
ES2214166T1 (es) * 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN100447239C (zh) * 2005-04-08 2008-12-31 上海组织工程研究与开发中心 冻存胚胎干细胞的复苏方法
US8709797B2 (en) 2006-06-20 2014-04-29 Cook General Biotechnology Llc Systems and methods for cryopreservation of cells
JPWO2011021618A1 (ja) * 2009-08-19 2013-01-24 タカラバイオ株式会社 細胞の保存方法
CN101990888B (zh) * 2009-08-31 2014-04-30 深圳市北科生物科技有限公司 干细胞冻存液及干细胞的冻存方法
CN102160546B (zh) * 2010-02-24 2016-01-20 库克通用生物科技有限责任公司 冷冻保存细胞的系统和方法
JP5341059B2 (ja) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
CN102511471B (zh) * 2011-12-15 2013-08-28 成都清科生物科技有限公司 一种间充质干细胞冻存液及其制备方法
EP2721930A1 (en) * 2012-10-19 2014-04-23 Serumwerk Bernburg AG Solution for cryopreservation, method of manufacturing the same, and its use
CN105394026B (zh) * 2015-10-31 2017-09-29 北京军科联合干细胞生物科技有限公司 一种造血干细胞冻存新方法

Also Published As

Publication number Publication date
US20170332623A1 (en) 2017-11-23
JP2019510042A (ja) 2019-04-11
AU2017241626A1 (en) 2018-11-22
AU2017241626B2 (en) 2022-03-31
EP3435762A1 (en) 2019-02-06
CN109195445A (zh) 2019-01-11
CA3022685A1 (en) 2017-10-05
US20200383317A1 (en) 2020-12-10
WO2017172679A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
CR20170492A (es) Composiciones de ácido obeticólico y métodos de uso.
BR112017014060A2 (pt) composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas
BR112013006341A2 (pt) formulações agrícolas líquidas com estabilidade aperfeiçoada
BR112015022119A2 (pt) Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
EA201590518A1 (ru) Стабильные водные составы адалимумаба
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112014003139A2 (pt) musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso
BR112015018508A2 (pt) moduladores de enzimas modificadoras de metila, suas composições e uso
BR112014032910A2 (pt) solfactants de éter de glicerina etoxilado
BR112017006533A2 (pt) usos de trealose em suspensões celulares
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
BR112015000520A2 (pt) agente de espessamento estável com lipase
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
BR112015025451A2 (pt) sistemas biocidas e métodos de utilização
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]